Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
NCT03221036

Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Led by Takeda · Updated on 2025-12-23

402

Participants Needed

36

Research Sites

547 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to assess the effect of vedolizumab intravenous IV as induction and maintenance treatment in Chinese participants with moderately to severely active ulcerative colitis (UC).

CONDITIONS

Official Title

Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of ulcerative colitis established at least 3 months before screening by clinical and endoscopic evidence with histopathology report or sufficient supporting evidence
  • Moderately to severely active ulcerative colitis with a complete Mayo score of 6-12 and endoscopic subscore 652 within 10 days prior to first dose
  • Ulcerative colitis extending at least 15 cm from the rectum
  • For extensive colitis or pancolitis >8 years, or left-sided colitis >12 years, documented surveillance colonoscopy within 12 months
  • Up-to-date colorectal cancer surveillance for participants with risk factors such as family history or age over 50
  • Inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators, or TNF-alpha antagonists
Not Eligible

You will not qualify if you...

  • Presence of abdominal abscess or toxic megacolon at screening
  • History of extensive colonic resection, subtotal or total colectomy
  • Existing ileostomy, colostomy, or fixed symptomatic intestinal stenosis (reversed ileostomy or colostomy may be acceptable)
  • Prior use of approved or investigational anti-integrin or MAdCAM-1 antagonist drugs, or rituximab
  • Use of topical 5-ASA or corticosteroid enemas/suppositories or traditional Chinese medications within 2 weeks before first dose
  • Current or planned surgical intervention for ulcerative colitis during the study
  • History or evidence of unresected adenomatous colonic polyps or colonic mucosal dysplasia
  • Diagnosis of Crohn's enterocolitis, indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease with colitis, or microscopic colitis
  • Recent (within 28 days) treatment for C. difficile infection or other intestinal pathogens
  • Chronic hepatitis B or C infection
  • Active or latent tuberculosis
  • Congenital or acquired immunodeficiency including HIV infection or organ transplantation
  • History of malignancy except certain treated skin or cervical cancers
  • History of major neurological disorders including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease
  • Positive screening for progressive multifocal leukoencephalopathy (PML) symptoms

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 36 locations

1

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China, 230022

Completed

2

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China, 100050

Completed

3

The First Affiliated Hospital of Nanchang University

Beijing, Beijing Municipality, China, 100730

Completed

4

Second Affiliated Hospital of Army Medical University, PLA

Chongqing, Chongqing Municipality, China, 400037

Completed

5

Army Specialty Medical Center of The Chinese People's Liberation Army

Chongqing, Chongqing Municipality, China, 400042

Completed

6

The 900th Hospital of The Chinese People's Liberation Army Joint Logistics Support Force

Fuzhou, Fujian, China, 350025

Completed

7

Zhongshan Hospital Xiamen University

Xiamen, Fujian, China, 361004

Actively Recruiting

8

Zhangzhou Municipal Hospital of Fujian Province

Zhangzhou, Fujian, China, 363000

Completed

9

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China, 510080

Completed

10

The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China, 510080

Completed

11

Nanfang Hospital of Southern Medical University

Guangzhou, Guangdong, China, 510515

Completed

12

The Sixth Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China, 510655

Actively Recruiting

13

Meizhou People's Hospital

Meizhou, Guangdong, China, 514031

Actively Recruiting

14

The Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, China, 050000

Actively Recruiting

15

Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China, 430022

Completed

16

Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China, 430030

Actively Recruiting

17

Renmin Hospital, Wuhan University

Wuhan, Hubei, China, 430060

Completed

18

Xiangya Hospital of Central South University

Changsha, Hunan, China, 410008

Actively Recruiting

19

The First Hospital of Jilin University

Changsha, Hunan, China, 410011

Actively Recruiting

20

The Third Xiangya Hospital of Central South University

Changsha, Hunan, China, 410013

Completed

21

The Affiliated Hospital of Nanjing University Medical School

Nanjing, Jiangsu, China, 210008

Completed

22

Jiangsu Province Hospital

Nanjing, Jiangsu, China, 210029

Actively Recruiting

23

Wuxi People's Hospital

Wuxi, Jiangsu, China, 214023

Completed

24

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China, 330006

Actively Recruiting

25

The First Hospital of Jilin University

Changchun, Jilin, China, 130021

Completed

26

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China, 110022

Actively Recruiting

27

General Hospital of Ningxia Medical University

Yinchuan, Ningxia, China, 750004

Completed

28

The First Affiliated Hospital of Nanchang University

Shanghai, Shanghai Municipality, China, 100730

Completed

29

Ruijin Hospital of Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China, 200020

Actively Recruiting

30

Zhongshan Hospital Fudan University

Shanghai, Shanghai Municipality, China, 200032

Completed

31

The Sixth Affiliated Hospital of Sun Yat-sen University

Shanghai, Shanghai Municipality, China, 200072

Completed

32

Shanxi Provincial People's Hospital

Taiyuan, Shanxi, China, 030012

Actively Recruiting

33

West China Hospital, Sichuan University

Chengdu, Sichuan, China, 610041

Completed

34

First Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, China, 650032

Completed

35

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310009

Actively Recruiting

36

Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

Hangzhou, Zhejiang, China, 310016

Completed

Loading map...

Research Team

T

Takeda Study Registration Call Center

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here